gsk medical affairs jobs near london

POSTER: Treatment patterns and time to next treatment among OC patients in a real-life setting in Finland: the OCRWE-Finland study (ASCO Encore), 3. Search jobs Life at GSK Careers . [Poster No. Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. Matching-Adjusted Indirect Comparisons (MAIC) of Safety Between Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM), 9. Dostarlimab is being investigated as a monotherapy in DNA mismatch repair?deficient cancers, including endometrial cancer, and in unselected populations in combination with other therapies. POSTER: Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified by Exposure to Lenalidomide or Anti-CD38 Therapy and Double-class Refractory Status: A Retrospective Electronic Health Record Database Study, 4. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Front Immunol. GSK plc. Poly ADP ribose polymerases (PARPs) are a family of enzymes involved in many functions, including DNA repair, gene expression, cellular signaling, and base excision repairs. Dransfield MT, Halpin DMG, Han MK, et al. Se continui a visualizzare Cho E-Y, Cho J-E, Jang S-H, et al. Singh AK, et al. Can we break that record on Sat 4/22? 805; Abstract A4294]. By creating this job alert, you agree to the LinkedIn User Agreement and Privacy Policy. P1483. Poster No. Stark A-K, Sriskantharjah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. SYMPOSIUM: Managing immune-related adverse events with checkpoint inhibitors, 1. Abstract Publication No. Ajude-nos a manter o Glassdoor seguro confirmando que voc uma pessoa de 3. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. Molfino NA, Averell CM, Hahn BA, et al. Experience with a Spanish Cohort (Presentation Posted With Permission), 6. 8. PUBLICATION ONLY: Real-World Treatment Patterns of Maintenance therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: Are Some Patients Missing Out? Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients? 1. Eur J Immunol. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, 6. Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial? ORAL PRESENTATION: Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability?high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study, 1.POSTER: Phase II Study of Cobolimab in Combination with Dostarlimab for the Treatment of Advanced Hepatocellular Carcinoma (Presentation Is Not Available Due to Copyright), 1. POSTER: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response, 2. Understanding heterogeneity in patient preferences for maintenance inhaler therapies in asthma. Leverage your professional network, and get hired. para informarnos de que tienes problemas. Goodall E, Wood R, Numbere B, et al. 2018;7(5):e1426519. Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM), 1. Initiating Mepolizumab. TSR-033 is a humanized LAG-3 antagonist IgG4 mAb that is being investigated as a monotherapy and in combination with anti?PD-1 therapy in advanced solid tumors. ORAL PRESENTATION: Shapiro A, et al. Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis ?of REALITI-A? Hemoglobin Stability in the ASCEND-D and ND trials. Stability Calculator, Click here if you are not a US Healthcare Professional, Patient, or Caregiver. POSTER: First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort, 2. [Oral presentation available here; Abstract A4211]. Psychometric Properties of the SF-36 Vitality Scale ?in Patients With Anemia of Chronic Kidney Disease. 3. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. ENCORE: Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma, 18. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. 5. (Poster No. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. [Poster No. 60 ), 2. Obrador GT, et al. Plain Language Summary [HCP USE ONLY]: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 4. PUBLICATION ONLY: Comparison of survival outcomes between dostarlimab and comparator treatments in patients with advanced/recurrent endometrial cancer in England: matching-adjusted indirect comparisons, 16. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. [Poster No. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. GSK US Medical Affairs Scientific Director, Specialty Pipeline Durham, NC 30d+ $95K-$138K Per Year (Glassdoor est.) 1. Poster No. para nos informar sobre o problema. Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013-2018. Cancer Discov. Sustained Clinical Benefits in Patients With Chronic Rhinosinusitis With Nasal Polyps 24 Weeks Post-mepolizumab Treatment. 3. Patient preferences for dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple therapy. 3888792. Encore: DREAMM-1: Patient Perspectives From the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 4. Insights From Allergy Practice (Poster No. MOONSTONE: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With Platinum Resistant Ovarian Cancer (TiP), 5. Sule N, Fowler A, Kerstjens HA, et al. Time-Dependent Covariate Analysis of Hemoglobin Values ?on Risk of MACE in the ASCEND Trials. ORAL PRESENTATION: Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 3. NY-ESO-ImmTAC (immune mobilizing monoclonal TCR against cancer [IMCnyeso]) is a bifunctional soluble high-affinity T-cell receptor (TCR) specific for NY-ESO-1 that also engages the CD3 receptor on T cells. POSTER: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma(Presentation Is Not Available Due to Copyright), 3. Kerwin EM, Maltais F, Boucot IH, et al. GSK3745417 is a synthetic STING agonist that is being investigated as a monotherapy and in combination with pembrolizumab in relapsed/refractory solid tumors. ?Post hoc Analyses of ASCEND-ND and ASCEND-D, Obrador GT, et al. Apply to Public Health Nurse, Medical Director, Senior Director and more! 4. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. Rothnie K, Han X, Bengtson L, et al. Singh AK, et al. [Poster No. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. ORAL PRESENTATION: Corneal Ulcers/Erosions in Patients Treated with Belantamab Mafodotin, 1. Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 5. Averell CM, Hahn BA, Zografos L, et al. POSTER: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 3. 2018;9:947. Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-? #ppswgg#myoldmedss#safedisposallz, Real conversations generate impactful change. 6. Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. 1. Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. 1. Phase 2, Multi Arm Study of Niraparib in Combination With a PD 1 Inhibitor in Patients With Non Small Cell Lung Cancer: JASPER, Bintrafusp Alfa Bifunctional TGF-? The Sustained OCS-Sparing Effect of Mepolizumab: Results From the Real-World REALITI-A Study at 2 Years. We have set appropriate and ambitious aspirations for ethnic diversity in ourUS Early Talent Programfor apprentices and graduate trainees. Blood. A Population Study. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. Moraes F, Abreu G, Nogueira T, et al. 2018;10(424):eaan5488. DREAMM-2: Single-Agent Belantamab Mafodotin in Patients With RRMM?Outcomes by Prior Therapies [Poster not available for viewing due to copyright restrictions], 6. Singh AK, et al. Affairs portal to a separate website maintained by 3. Meta-analysis From Two Phase 3 Trials. ur employees and our values are at the heart of everything we do. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. 3. GlaxoSmithKline. ?Post hoc Analyses of ASCEND-ND and ASCEND-D, 1. Johansen K, et al. Ismaila A, Haeussler K, Czira A, et al. POSTER: Trial in Progress: Phase II Study of Niraparib and Dostarlimab for the Treatment of Germline or Somatic Homologous Recombination Repair Mutated Metastatic Pancreatic Cancer (Presentation Posted With Permission), 1. 1. PO1437, 2. Bintrafusp alfa is a bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor ? P474; Abstract A3997]. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. Strobel MJ, Alves D, Roufosse F, et al. Maximal Change in Erythropoietin in Hemodialysis ?Patients Receiving Daprodustat or Epoetin Alfa ?in the ASCEND-TD Trial, 9. Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD? 1-Year Outcomes by Prior Therapies, 6. Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD? Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA, 11. 1. Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study, 1. Hosking L, Yeo A, Hoffman J, et al. Liu M, Bagnasco D, Matucci A, et al. 2. Association between TGF-? ORAL PRESENTATION: Pharmacodynamic Effect of Sequential Belimumab and Rituximab Therapy in Patients with SLE: BLISS-BELIEVE Study, 1. POSTER: Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study, 7. PO0487, 1. 5. GSK is committed to the discovery and development of new vaccines and oncology and hematology compounds that leverage patient-driven science to deliver improved outcomes for more patients. 3. POSTER: A report of the postmarketing spontaneous safety data over 24 years for GSK?s measles-mumps-rubella (MMR) vaccine. Ismaila A, Haeussler K, Czira A, et al. Liu M, Bagnasco D, Matucci A, et al. Whittaker HR, Rothnie K, Quint JK. Strobel M, Alves D, Roufosse F, et al. [Poster No. www.fda.gov/medwatch. 373. Identifying drivers of patients? 14. Presentation with Audio: Voice Recording: A phase 1b/2, open-label study of bintrafusp alfa with chemotherapy in patients with stage IV NSCLC, 1. Cole AL, Moretz C, Mu G, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. This information does not take the place of talking with your doctor. Poster No. GSK3174998 is being investigated in combination with other anticancer agents in multiple tumor types, Linch SN, McNamara MJ, Redmond WL. J Clin Oncol. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM](Encore), 6. [Poster No. 2. 10. Lamentamos pelo inconveniente. 336), 1. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. 6. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. ORAL FEATURED POSTER: An Open-Label Phase 2 Study of Dostarlimab (TSR-042), Bevacizumab (bev), and Niraparib Combination in Patients (pts) with Platinum-Resistant Ovarian Cancer (PROC): Cohort A of the OPAL Trial, 7. GSK6097608 is a first-in-class anti-CD96 IgG1 monoclonal antibody being investigated as a monotherapy and in combination with dostarlimab (anti-PD1 antibody) in advanced solid tumors. Our HR team works with external experts to define best practices. 2. GSK3326595, a selective inhibitor of PRMT5, is being investigated as a monotherapy in solid tumors and in combination with other therapies in various hematologic malignancies. peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2). Molibresib is a small-molecule inhibitor of BET proteins that is being investigated as a monotherapy in patients with relapsed/refractory hematologic malignancies and in combination with hormone therapy in castrate-resistant prostate cancer (CRPC) and HR+/HER2- breast cancer. GSK is an Equal Opportunity/Affirmative Action Employer. GSK3377794 is an adoptive cell therapy that uses genetically engineered autologous T cells expressing NY-ESO-1? 11. Chaudhuri R, Canonica GW, Bals R, et al. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. It is being investigated as monotherapy and in combination with other anticancer agents in various malignancies. Jobs; Companies; . POSTER: The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 MOMENTUM study, 9. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, 4. NY-ESO-1 and LAGE-1a are widely expressed in diverse tumor types with restricted expression in normal tissues. Tai Y-T, Anderson KC. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. 2. A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States (ESGO Encore), 3. P742; Abstract A4771]. 2016;6(4):446-459. Sign in to create your job alert for Gsk Medical Affairs jobs in United States. Mularski RA, Drummond MB, Jain R, et al. 2. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3. Rothnie KJ, Bancroft T, Bogart M, et al. Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWiST analysis of the ENGOT OV16/NOVA trial, 2. and Physicians? to let us know you're having trouble. Expression of myeloma cell BCMA and soluble BCMA in relapsed and refractory multiple myeloma subjects treated with GSK2857916 in BMA117159, 4. Patient Experience Information (PEI) and Patient Involvement in Health Technology Assessment (HTA) Processes in 7 European Countries Using Immuno-Oncology Examples: How Can the Patient Voice Make an Impact? Get notified about new Gsk Medical Affairs jobs in United States. 1. Presentation: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 2. A Phase 1 Dose Escalation Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors, 3. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. April 27, 2023. Zejula [summary of product characteristics]. Review the package insert for important safety information. Sansbury LB, Hinds D, Chao J, et al. The information is not intended as medical advice. Recovery of Ocular Events with Longer-term Follow-up in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM), 4. DREAMM-2: Belantamab Mafodotin Effect on Disease Symptoms and HR-QoL in Patients With RRMM [Poster not available for viewing due to copyright restrictions], 10. Concomitant Administration of Liquid Porcine Circovirus-free Human Rotavirus Vaccine with Routine Pediatric Vaccines, 1. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? GSK 4.2 Brentford Delivering the field medical and scientific engagement plan. Bogart M, Han X, Bengtson L, et al. The anti-BCMA antibody-drug conjugate belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated anti-tumor response, and in combination with an OX40 agonist potentiates in vivo activity. Sort by: relevance - date. Further information relevant to the local environment is available from the company or via the Product Information. Get email updates for new Gsk Medical Affairs jobs in United States. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. and physicians? Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma, 5. 3888792. Bogart M, Chastek B, White J, et al. Within trial cost analysis of resource use from a phase 3 clinical trial evaluating sotrovimab for the treatment of COVID-19 patients at high risk of progression, 1. We are led by our purpose: to get ahead of disease together. POSTER: Real-World Belantamab Mafodotin (Belamaf) Use: A US Retrospective Longitudinal Pharmacy and Medical Open-Source Claims Database Assessment, 1. 2017;31(2):101-1261. Use of Mepolizumab among Individuals with Asthma in the U.S. [Poster No. The PI3K/AKT and phosphatase and tensin homolog (PTEN) pathways are among the most frequently mutated pathways in human cancers. The winners found large companies with a big Hispanic workforce and created solutions including an employer caregiver toolkit and caretaker programs. Keir HR, Richardson H, Mayhew D, et al. Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is involved in driving necroptosis, a proinflammatory form of cell death that may promote metastasis and suppress T-cell?driven antitumor immunity. POSTER: Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States[GMA ROYAL study], 1. Exposure-Response Analysis of the PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with Ovarian Cancer, 1. POSTER: Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in patients with recurrent ovarian cancer, 3. Learn how to prepare, what will be collected, and how to safely store your medicine until the event at: MyOldMeds.com/blogrV. Singh AK, et al. 2. PUBLICATION ONLY: DREAMM-1: Patient Perspectives from the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma (RRMM), 25. [Poster No. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. Maximal Change in Erythropoietin in Hemodialysis ?Patients Receiving Daprodustat or Epoetin Alfa ?in the ASCEND-TD Trial, Causes of Death in Patients with Anemia of ?Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial. We set an aspirational goal here in the US. Epigenetics. Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility. Gsk Medical Affairs jobs Sort by: relevance - date 55 jobs EU Medical Affairs Lead, Hematology GSK 4.1 Brentford TW8 London, ENG. Identifying drivers of patients? Encore: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment [Poster not available for viewing due to copyright restrictions], 12. POSTER: Lokhandwala et al. 1. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. Immunotherapy. Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting ?2-agonist. POSTER: Management of Immune-Related Adverse Events in Patients with Solid Tumors Treated with Dostarlimab in the GARNET Study, 3. P713; Abstract A1828], 10. Triple checkpoint blockade targeting PD-1, TIM-3, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations, 1. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial (AACR ENCORE), 9. The estimated total pay for a Medical Science Liaison at GSK is $234,850 per year. Wechsler M, Kovalszki A, J Silver, et al. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. 2. A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. Kovalszki A, Wechsler M, Silver J, et al. 178 Medical Affairs Jobs in London, England, United Kingdom (9 new) Regulatory Affairs Officer / RAQA Officer Hays Uxbridge, England, United Kingdom Be an early applicant 4 weeks ago. Rates of Major Events in Untreated Patients Diagnosed ?With Anemia of CKD in France?? All rights reserved. POSTER: Early COVID-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab. See product details, storage & handling info for GSK vaccines, and more. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis, 3. Real-World Impact of Systemic Corticosteroid (SCS) Exposure on Healthcare Resource Utilization (HRU) due to SCS-Related Complication among Patients with Asthma in the US? DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 9. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States. 4. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing.Poster F\AAFP 2021, 1. 1. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor(Encore), 1. 817; Abstract A4306]. Patient Perceptions of Treatment Success in Uncomplicated Urinary Tract Infection. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. 2. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. Evaluation of immune phenotypes and gene expression profiles in tumors from patients treated with bintrafusp alfa, 4. Effects of Daprodustat on Hemoglobin and Quality of Life in Patients With CKD: Results of the ASCEND-NHQ Randomized, Double-blind, Placebo-controlled Trial, 4. The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus, 3. Onze Note: The search will retrieve any scientific documents from the medical information database where the search terms match either the title or content of the document. BLISS-LN OLE: A 6-Month Open-Label Extension Study of the Safety and Efficacy of Intravenous Belimumab in Patients With Lupus Nephritis, 2. Tumor necrosis factor receptor superfamily, member 4 (OX40 [CD134]) is expressed by T cells during antigen-specific priming. ORAL FEATURED POSTER: Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy With Bevacizumab, 6. A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML). Here at GSK, we unite science, technology and talent to get ahead of disease together. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count, 9. 2. . Blood. Vice President, Country Medical Director, UK & Ireland. 1. 1. 8. When expanded it provides a list of search options that will switch the search inputs to match the current selection. Real World Evidence in Asthma: Pulmonary Function and Asthma Control in Respiratory Specialty Clinics in the US. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 ? POSTER: Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study (IGCS ENCORE), 12.

Sandra Grace Martinez Land Commissioner, Hummingbird Poop Images, Where Does Curly Hair Come From In Europe, How To Reinvest Dividends On Merrill Edge, Articles G